Dr. Hamilton on the Evaluation of Lucitanib/Nivolumab in Gynecologic Cancers

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at the Sarah Cannon Research Institute, discusses the phase 2 LIO-1 trial (NCT04042116) evaluation of lucitanib and nivolumab (Opdivo) across different gynecologic cancer subtypes.

The phase 2 portion of the LIO-1 trial will examine the combination in several gynecologic cohorts, according to Hamilton. These cohorts include patients with ovarian cancer, endometrial cancer, and cervical cancer, with a fourth cohort examining the combination in patients with clear cell cancer, of either endometrial or ovarian origin. Investigators will begin with a 6-mg dose and increase to 8 mg and 10 mg, as tolerated by patients, Hamilton concludes.